In its second Blueprint for Change Programme business case, Novo Nordisk reports that its Triple Bottom Line business principle, balancing economic, social and environmental decisions, has created ...

Novo Nordisk stock plunged after CagriSema missed against Eli Lilly’s Zepbound, but new obesity drug data and a low valuation ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 ...

The past year hasn't been kind to Novo. Every trial headline, reimbursement rumor, and GLP-1 pricing whisper has sparked the same reflex response: a 5–10% intraday punishment, regardless of whether ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability. The TrumpRx platform ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...

Novo Nordisk's new indications for semaglutide and its attractive pipeline could allow it to bounce back. Intuitive Surgical should remain the leader in its niche despite increased competition. Both ...